Reuters -- Opexa Therapeutics Inc said Swiss drug-maker Novartis has acquired its stem cell technology, which was in early preclinical development, sending its shares up 70 percent before the bell.
Reuters -- Opexa Therapeutics Inc said Swiss drug-maker Novartis has acquired its stem cell technology, which was in early preclinical development, sending its shares up 70 percent before the bell.
